Cancer name Prostate Cancer
Cancer Type PRAD
Immunotherapy type Cancer Vaccine
Treatment DCVAC/PCa(autologous DCs pulsed with the killed LNCaP cell line)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature PRF1
Official Symbol PRF1
Mode of action TRAN_R_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trial phase 1/2
Description Several genes related to CD8/NK (natural killer) cell cytotoxicity (Fas, Fas-L, granzyme, granulysin, PRF1) were significantly overexpressed in the group of responders compared with non-responders.
PMID 28948333
Title Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer